CRISPR Therapeutics CRSP Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's total liabilities?
- CRISPR Therapeutics (CRSP) reported total liabilities of $911.26M in Q1 2026.
- How has CRISPR Therapeutics's total liabilities changed year-over-year?
- CRISPR Therapeutics's total liabilities increased by 170.5% year-over-year, from $336.94M to $911.26M.
- What is the long-term trend for CRISPR Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's total liabilities has grown at a 16.0% compound annual growth rate (CAGR), from $163.73M to $343.43M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.